Postpartum depression (PPD), a so-far untapped market, is large enough for multiple players with 1 in 7 women diagnosed with the condition that has no specific therapies approved by the FDA. But Sage $SAGE, which reported impressive late-stage data on its pill in severe PPD patients on Monday, is not worried about potential competition.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,